ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Yoshida, Takeshi ^a   Song, Lanxi ^a   Bai, Yun ^a   Kinose, Fumi ^a   Li, Jiannong ^a   Ohaegbulam, Kim C ^a   Muñoz Antonia, Teresita ^a   Qu, Xiaotao ^a   Eschrich, Steven ^a   Uramoto, Hidetaka ^b   Tanaka, Fumihiro ^b   Nasarre, Patrick ^c   Gemmill, Robert M ^c   Roche, Joëlle ^c   Drabkin, Harry A ^c   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MESSENGER RNA; MICRORNA 200C; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE INHIBITOR; SMAD PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN; ZINC FINGER PROTEIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; PROTEIN KINASE INHIBITOR; ZEB1 PROTEIN, HUMAN;

ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84959255800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147344     Document Type: Article

References (61)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. doi: 10.1056/NEJMoa0810699 PMID: 19692680
2. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. PMID: 15728811
3. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43. PMID: 17463250
4. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005; 11(24 Pt 1):8686-98. PMID: 16361555
5. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005; 65(20):9455-62. PMID: 16230409
6. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like nonsmall cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008; 25(8):843-54. doi: 10.1007/s10585-008-9200-4 PMID: 18696232
7. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66(2):944-50. PMID: 16424029
8. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010; 107(35):15535-40. doi: 10.1073/pnas.1009472107 PMID: 20713723
9. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, et al. Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib. J Thorac Oncol. 2011; 6:1152-61. doi: 10.1097/JTO.0b013e318216ee52 PMID: 21597390
10. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer. 2011; 30:2513-7.
11. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science translational medicine. 2011; 3(75):75ra26. doi: 10.1126/scitranslmed.3002003 PMID: 21430269
12. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013; 2:e39. doi: 10.1038/oncsis.2013.4 PMID: 23552882
13. Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res. 2010; 70(17):6715-24. doi: 10.1158/0008-5472.CAN-10-1377 PMID: 20736375
14. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011; 300(1):66-78. doi: 10.1016/j.canlet.2010.09.007 PMID: 20980099
15. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2:442-454. PMID: 12189386
16. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature reviews Cancer. 2013; 13(2):97-110. doi: 10.1038/nrc3447 PMID: 23344542
17. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178-196. doi: 10.1038/nrm3758 PMID: 24556840
18. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7:131-142. PMID: 16493418
19. Sleeman JP, Thiery JP. SnapShot: The epithelial-mesenchymal transition. Cell. 2011; 145:162.e161.
20. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009; 1796:75-90. doi: 10.1016/j.bbcan.2009.03.002 PMID: 19306912
21. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29:4741-4751. doi: 10.1038/onc.2010.215 PMID: 20531305
22. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clinical and translational medicine. 2014; 3:17. doi: 10.1186/2001-1326-3-17 PMID: 25050175
23. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014; 31:56-66. doi: 10.1016/j.ceb.2014.09.001 PMID: 25240174
24. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014; 7:re8. doi: 10.1126/scisignal.2005189 PMID: 25249658
25. Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. Embo j. 2010; 29:1803-1816. doi: 10.1038/emboj. 2010.63 PMID: 20389281
26. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nature structural & molecular biology. 2011; 18(8):867-74.
27. Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers. 2013; 5(2):334-56. doi: 10.3390/cancers5020334 PMID: 24216980
28. Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, et al. Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Res 2015; 75:1789-1800. doi: 10.1158/0008-5472.CAN-14-2535 PMID: 25744723
29. Kothari AN, Mi Z, Zapf M, Kuo PC. Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clinical and translational medicine. 2014; 3:35. doi: 10.1186/s40169-014-0035-0 PMID: 25343018
30. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10 (5):593-601. doi: 10.1038/ncb1722 PMID: 18376396
31. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283(22):14910-4. doi: 10.1074/jbc.C800074200 PMID: 18411277
32. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22(7):894-907. doi: 10.1101/gad.1640608 PMID: 18381893
33. Machida K, Eschrich S, Li J, Bai Y, Koomen J, Mayer BJ, et al. Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS One. 2010; 5(10):e13470. doi: 10.1371/journal. pone.0013470 PMID: 20976048
34. Hall JG, Eis PS, Law SM, Reynaldo LP, Prudent JR, Marshall DJ, et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci U S A. 2000; 97 (15):8272-7. PMID: 10890904
35. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. PMID: 6382953
36. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010; 6(4):291-9. doi: 10.1038/nchembio.332 PMID: 20190765
37. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003; 22(27):4150-65. PMID: 12833138
38. Haura EB, Muller A, Breitwieser FP, Li J, Grebien F, Colinge J, et al. Using iTRAQ combined with tandem affinity purification to enhance low-Abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res. 2010; 10(1):182-90. doi: 10.1021/pr100863f PMID: 20945942
39. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005; 24(21):3397-408. PMID: 15735721
40. Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T. Pathway mapping tools for analysis of high content data. Methods in molecular biology (Clifton, NJ). 2007; 356:319-50.
41. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nature protocols. 2007; 2(10):2366-82. PMID: 17947979
42. Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res. 2007; 67(18):8708-15. PMID: 17875711
43. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005; 2(1):e17. PMID: 15696205
44. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008; 118:2609-2619. doi: 10.1172/JCI34588 PMID: 18568074
45. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009; 69:3256-3261. doi: 10.1158/0008-5472.CAN-08-4055 PMID: 19351834
46. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005; 102(10):3788-93. PMID: 15731348
47. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science translational medicine. 2011; 3(90):90ra59. doi: 10.1126/scitranslmed.3002356 PMID: 21734175
48. La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, et al. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One. 2013; 8:e78656. doi: 10.1371/journal.pone.0078656 PMID: 24167634
49. Kakihana M, Ohira T, Chan D, Webster RB, Kato H, Drabkin HA, et al. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol. 2009; 4(12):1455-65. doi: 10.1097/JTO.0b013e3181bc9419 PMID: 20009910
50. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-59. doi: 10.1016/j. cell.2009.06.034 PMID: 19682730
51. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008; 68 (22):9532-40. doi: 10.1158/0008-5472.CAN-08-3082 PMID: 19010930
52. Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends in pharmacological sciences. 2014; 35(9):479-88. doi: 10.1016/j.tips. 2014.06.006 PMID: 25042456
53. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature communications. 2014; 5:5241. doi: 10.1038/ncomms6241 PMID: 25348003
54. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A. 2009; 106 (46):19503-8. doi: 10.1073/pnas.0905056106 PMID: 19850869
55. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009; 137(1):361-71, 71 e1-5. doi: 10.1053/j.gastro.2009.04.004 PMID: 19362090
56. Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan X, et al. Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol. 2010; 42 (9):1489-97. doi: 10.1016/j.biocel.2010.05.006 PMID: 20580679
57. Bedi U, Mishra VK, Wasilewski D, Scheel C, Johnsen SA. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget. 2014; 5(8):2016-29. PMID: 24840099
58. Mishra VK, Johnsen SA. Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression. Cell and tissue research. 2014; 356(3):617-30. doi: 10.1007/s00441-014-1912-y PMID: 24833164
59. Wu CY, Tsai YP, Wu MZ, Teng SC, Wu KJ. Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends in genetics: TIG. 2012; 28(9):454-63. doi: 10. 1016/j.tig.2012.05.005 PMID: 22717049
60. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. doi: 10.1016/j. cell.2010.02.027 PMID: 20371346
61. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24 (37):5764-74. PMID: 16123809